CookieStocks
REGN beat EPS estimates by 21.8%. Quarter ended Sep 30, 2026. Beat estimates in 4 of the last 4 quarters.

2026-10-30 · REGN

REGN beat EPS estimates by 21.8%

Quarter ended Sep 30, 2026. Beat estimates in 4 of the last 4 quarters.

The story in plain words

Friday, October 30, 2026. REGN beat EPS estimates by 21.8%. Quarter ended Sep 30, 2026. Beat estimates in 4 of the last 4 quarters.

What the data shows for Regeneron Pharmaceuticals (REGN): EPS $20.07 vs a consensus estimate of $16.48. EPS +35.5% vs the same quarter a year earlier. Revenue $5.1B, +36.3% vs a year earlier.

Worked out from that data: Beat estimates in 4 of the last 4 quarters.

About the company: Regeneron Pharmaceuticals trades as REGN and is part of the S&P 500, in the Health Care sector (Biotechnology), headquartered in Tarrytown, New York, founded in 1988.

This is one of CookieStocks’ daily stock stories about S&P 500 earnings reports: reported earnings per share against expectations, with the history behind them. Stories are found automatically each trading day from market data and SEC filings, and every claim is labelled as observed, calculated or a possible contributor. Statistics only, not investment advice.

Prove it

Every claim on the graphic, labelled: observed (straight from the data), calculated (worked out from it), or possible contributor (lines up in time, not a confirmed cause).

  • OBSERVED
    EPS $20.07 vs a consensus estimate of $16.48Oct 30, 2026, 4:00 PM ET
  • OBSERVED
    EPS +35.5% vs the same quarter a year earlierSource: SEC EDGAR · Oct 30, 2026, 4:00 PM ET
  • OBSERVED
    Revenue $5.1B, +36.3% vs a year earlierSource: SEC EDGAR · Oct 30, 2026, 4:00 PM ET
  • CALCULATED
    Beat estimates in 4 of the last 4 quartersHow: count of quarters with EPS ≥ estimate

Regeneron Pharmaceuticals (REGN) financials and filings →

More stories

Statistics only, not investment advice. Past moves don’t predict future ones. Data as of Oct 30, 2026, 4:35 PM ET.